| Interactions between Xenobiotics and DME (XEOTIC)
|
| Natural Product(s), Extract(s) or Medicine(s) |
| Natural Product |
Click to Show/Hide the Full List of Xenobiotics: 2 Xenobiotics
|
| Baicalein |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01212
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Baicalein inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Cinnamic aldehyde |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01253
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Natural Product |
| DME Modulation |
Cinnamic aldehyde inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Pharmaceutical Agent(s) |
| Approved/Marketed Drug |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Ceftazidime hydrate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO02786
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug Marketed but not Approved by US FDA |
| DME Modulation |
Ceftazidime hydrate inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Drug in Phase 3 Clinical Trial |
Click to Show/Hide the Full List of Xenobiotics: 3 Xenobiotics
|
| Curcumin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00683
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Curcumin inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Epigallocatechin gallate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00613
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Epigallocatechin gallate inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Resveratrol |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO00568
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Highest Clinical Status: Phase 3 |
| DME Modulation |
Resveratrol inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Preclinical/Patented Drug |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| Esculetin |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01291
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Drug in Preclinical Study |
| DME Modulation |
Esculetin inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Investigative Agent |
Click to Show/Hide the Full List of Xenobiotics: 3 Xenobiotics
|
| Esculin hydrate |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO03324
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
Esculin hydrate inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Farnesol |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01298
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
Farnesol inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| L-Canavanine |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO03812
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Investigative Agent |
| DME Modulation |
L-Canavanine inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
| Other Chemical Compound(s) or Element(s) |
| Chemical Compound |
Click to Show/Hide the Full List of Xenobiotics: 1 Xenobiotics
|
| 6-Fluoroanthranilic acid |
Click to Show/Hide the Detail |
Inhibition |
| XEOTIC ID |
XEO01933
XEOTIC Info
|
Gene Form |
Protein |
| Classification |
Chemical Compound |
| DME Modulation |
6-Fluoroanthranilic acid inhibits the drug-metabolizing activity of Beta-lactamase (blaB) from Burkholderia multivorans |
[1] |
|
|
|
|
|
|